MCAM and neoplasm: Functionalized hydrogels equipped with targeted ligands or antibodies have been designed to recognize melanoma-specific biomarkers, such as glycoprotein 100 (gp100) and melanoma cell adhesion molecule (MCAM), ensuring better accumulation of the drug in the tumor microenvironment while reducing systemic side effects.